Attention AACR-NCI-EORTC Molecular Targets Conference Registrants - Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 10 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 7 8 9 10 presentations: 1 to 25 of 237
Neratinib in HER2 or HER3 mutant solid tumors: SUMMIT, a global, multi-histology, open-label, phase 2 "basket" study
David M Hyman
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2017 on April 2, 2017 12:45 PM-3:00 PM
Discussant
Howard Burris
Sarah Cannon Research Institute, Nashville, TN, United States
from AACR Annual Meeting 2017 on April 2, 2017 12:45 PM-3:00 PM
A Phase IB study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors
Jayesh Desai
Royal Melbourne Hospital, Melbourne, Australia
from AACR Annual Meeting 2017 on April 2, 2017 12:45 PM-3:00 PM
Activity of the ERK1/2 inhibitor ulixertinib (BVD-523) in patients with BRAF and NRAS mutant melanoma
Ryan J Sullivan
Harvard Medical School/MGH, Boston, MA, United States
from AACR Annual Meeting 2017 on April 2, 2017 12:45 PM-3:00 PM
Discussant
Alex A. Adjei
Mayo Clinic, Rochester, MN, United States
from AACR Annual Meeting 2017 on April 2, 2017 12:45 PM-3:00 PM
European pediatric precision medicine program in recurrent tumors: first results from MAPPYACTS molecular profiling trial towards AcSe-ESMART proof-of-concept study
Birgit Geoerger
Inst. Gustave Roussy, Villejuif, France
from AACR Annual Meeting 2017 on April 2, 2017 12:45 PM-3:00 PM
Discussant
Yael P Mosse
Children's Hospital of Philadelphia, Philadelphia, PA, United States
from AACR Annual Meeting 2017 on April 2, 2017 12:45 PM-3:00 PM
Final results of the HERACLES trial in HER2-amplified colorectal cancer
Silvia Marsoni
Grande Ospedale Metropolitano Niguarda, Milano, Italy
from AACR Annual Meeting 2017 on April 2, 2017 12:45 PM-3:00 PM
Discussant
Rodrigo Dienstmann
Vall dĀ“Hebron Inst. of Oncology, Barcelona, Spain
from AACR Annual Meeting 2017 on April 2, 2017 12:45 PM-3:00 PM
Introduction: Why study environmental carcinogenesis?
Margaret L. Kripke
UT MD Anderson Cancer Center, Houston, TX, United States
from AACR Annual Meeting 2017 on April 1, 2017 10:15 AM-12:15 PM
Environmental carcinogenesis: Progress, challenges, and opportunities
John R. Bucher
National Institutes of Health, Research Triangle Park, NC, United States
from AACR Annual Meeting 2017 on April 1, 2017 10:15 AM-12:15 PM
Endocrine disruptors and reproductive cancers
Joan V Ruderman
Princeton University, Princeton, NJ, United States
from AACR Annual Meeting 2017 on April 1, 2017 10:15 AM-12:15 PM
Contribution of environmental exposures to childhood cancers
Philip J Landrigan
Icahn School of Medicine at Mt. Sinai, New York, NY, United States
from AACR Annual Meeting 2017 on April 1, 2017 10:15 AM-12:15 PM
Oncohistones and the epigenetic landscape of pediatric high-grade gliomas
Suzanne J. Baker
St. Jude Children's Research Hospital, Memphis, TN, United States
from AACR Annual Meeting 2017 on April 1, 2017 1:00 PM-3:00 PM
Histone modifications in pediatric sarcomas: Implications and possibilities
Janet Shipley
Inst. of Cancer Research, Sutton, United Kingdom
from AACR Annual Meeting 2017 on April 1, 2017 1:00 PM-3:00 PM
De-BAF-ling the role of SWI/SNF complex mutations in pediatric cancer development
Bernard E. Weissman
UNC Lineberger Comp. Cancer Ctr., Chapel Hill, NC, United States
from AACR Annual Meeting 2017 on April 1, 2017 1:00 PM-3:00 PM
Histone methylation in pediatric leukemias: A chance to rewrite the leukemic fate?
Kathrin Maria Bernt
The Children's Hospital of Philadelphia, Philadelphia, PA, United States
from AACR Annual Meeting 2017 on April 1, 2017 1:00 PM-3:00 PM
Invited Speaker
Peter C. Adamson
Children's Hospital of Philadelphia, Philadelphia, PA, United States
from AACR Annual Meeting 2017 on April 2, 2017 7:00 AM-8:00 AM
Invited Speaker
Kevin Oeffinger
Duke Cancer Institute, Duke University Medical Center, Durham, NC, United States
from AACR Annual Meeting 2017 on April 2, 2017 7:00 AM-8:00 AM
Targetable genetic bases of immune evasion in lymphoma
Margaret A. Shipp
Dana-Farber Cancer Institute, Boston, MA, United States
from AACR Annual Meeting 2017 on April 2, 2017 1:00 PM-2:45 PM
The Myc oncogene is a master regulator of the immune response
Dean W. Felsher
Stanford University School of Medicine, Stanford, CA, United States
from AACR Annual Meeting 2017 on April 2, 2017 1:00 PM-2:45 PM
Understanding success and failure of T-cell therapy for B-cell malignancies
Stanley R. Riddell
Fred Hutchinson Cancer Research Ctr., Seattle, WA, United States
from AACR Annual Meeting 2017 on April 2, 2017 1:00 PM-2:45 PM
Tracking brain tumors with regional accents
Richard J. Gilbertson
Cancer Research UK Cambridge Research Inst., Cambridge, United Kingdom
from AACR Annual Meeting 2017 on April 2, 2017 1:00 PM-2:45 PM
Neuronal activity drives pediatric high-grade glioma growth
Michelle L. Monje
Stanford Univ. School of Medicine, Stanford, CA, United States
from AACR Annual Meeting 2017 on April 2, 2017 1:00 PM-2:45 PM
Oncohistones: Genetic and epigenetic drivers of pediatric high-grade glioma
Suzanne J. Baker
St. Jude Children's Research Hospital, Memphis, TN, United States
from AACR Annual Meeting 2017 on April 2, 2017 1:00 PM-2:45 PM
<< first | < prev page: of 10 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 7 8 9 10 presentations: 1 to 25 of 237